CClinicalTrials.gg
CompletedNCT00347607Updated Oct 28, 2011

Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania

A Phase 4 interventional study of community surveillance and re-treatment in Trachoma, sponsored by Johns Hopkins University. Completed at 2 sites in 2 countries. Open to participants aged 12 Months to 7 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-28.

Sponsored by Johns Hopkins University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
2,700
Allocation
Randomized
Ages
12 Months to 7 Years
Sex
All
01

Study summary

After single, yearly, mass treatment of communities with azithromycin for active trachoma, what is the added effectiveness for reduction of trachoma and ocular C. trachomatis infection at one, two, and three years, relative to the added costs, of community-based surveillance and treatment of cases of severe trachoma (TI) semi-annually or every 4 months?

Read the detailed description

An important component of a trachoma control program is the effective use of antibiotics, particularly azithromycin, to reduce the pool of chlamydial ocular infection in the communities. A reduction in the pool of infection will reduce the likelihood of transmission and, coupled with effective hygiene and environmental changes, theoretically lead to reduction in disease to the point where active trachoma is no longer a public health problem. Our previous experience with the use of azithromycin for community treatment has shown that even with high rates of coverage, hyperendemic communities will start to experience re-emergent trachoma following treatment by one year. Therefore, it is urgent to determine if there is another treatment strategy for these villages to keep the pool of infection low, and eventually eliminated.A combination approach consisting of mass treatment at yearly intervals and surveillance with a targeted treatment approach in the interim period may be effective in maintaining the low rate of re-emergent disease.We propose to test the cost-effectiveness of three alternative strategies for the frequency of provision of azithromycin, in the context of the Tanzanian National Trachoma Control Program. The strategies have been developed to build on the epidemiological knowledge of trachoma in this area, to be locally appropriate in terms of feasibility and personnel, and to be consistent with the goal of enhancing community control of the program.

A total of nine villages in the Kongwa district of Tanzania will be randomized to one of three groups (a total of three villages per group). The nine villages, with active trachoma rates in pre-school children of 50% or greater, would be slated for enrollment in the National Program, but not currently receiving treatment. Surveys for active trachoma status would be carried out in 300 randomly selected, children ages 1-7 years (pre-school)in each village at baseline, at 6 months post mass treatment, and at one, two, and three years post baseline. The following treatment strategies will be used:

Control villages: Usual practice: The three villages randomized to this arm would receive mass treatment of the community once a year as part of the Tanzania National Trachoma Control program.

Intervention 1. Usual practice plus community surveillance for TI cases and treatment at 6 months: The three villages randomized to this arm would receive mass treatment, similar to the usual practice arm, but in addition, would have a cadre of community volunteers, trained to recognize TI. They will screen their neighborhoods, examining all pre-school children and mothers, and arrange with the health worker for another round of treatment for TI cases and their families at 6 months, and 18 months post baseline.

Intervention 2: Usual practice plus community surveillance for TI cases and treatment every 4 months: The three villages randomized to this arm would have an approach identical to intervention 1, but with surveillance and treatment of TI cases at 4 and 8 months instead of at 6 months.For the second year, they would have surveillance and treatment at 6 months.

Cost data on the community surveillance and treatment program will be collected throughout the first year. Analyses will focus on the additional benefit on reduction in prevalence of trachoma, and ocular C. trachomatis infection, at one, two, and three years of the two alternative strategies, relative to yearly mass treatment alone, and the cost-effectiveness of the three strategies.

02

Conditions studied

  • Trachoma

Browse trials for

Keywords

  • trachoma
  • chlamydia trachomatis
  • surveillance
  • azithromycin
03

Who can participate

Ages eligible
12 Months to 7 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • villages not in the Tanzania National Trachoma control Program in Kongwa, Tanzania
  • villages with population size less than 5,000
  • sentinel children: ages 1 year to 7 years

Exclusion criteria

Exclusion Criteria:

  • Village leadership refuses to allow village participation
  • sentinel children: previous history of treatment with azithromycin
  • sentinel children: another family member (child)already enrolled in study
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
2,700 participants

Interventions

  • Behavioralcommunity surveillance and re-treatment
05

What researchers measure

Primary outcomes

  1. trachoma

  2. ocular C. trachomatis

06

Study locations

2 sites
  • Johns Hopkins university
    Baltimore, Maryland 21205, United States
  • Kongwa Trachoma Project
    Kongwa, Dodoma, Tanzania
07

Registry details

Key details

Study ID
NCT00347607
Lead sponsor
Johns Hopkins University
Collaborators
International Trachoma Initiative
First posted
Jul 4, 2006
Start date
Apr 2002
Completion
Nov 2005
Last update
Oct 28, 2011

Study contacts

Sheila K West
principal investigator · Johns Hopkins University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2002. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion